Benzinga | Sep 15, 2021 04:06PM EDT

Travere Therapeutics And Vifor Pharma Announce Licensing Agreement For The Commercialization Of Sparsentan In Europe, Australia And New Zealand

Vifor Pharma obtains exclusive commercialization rights for sparsentan in Europe, Australia and New Zealand

Travere receives a $55 million upfront payment and is eligible for additional regulatory and commercial milestones, as well as tiered royalties on net sales

Sparsentan is a potential first-in-class treatment to address significant unmet medical needs in rare kidney disorders focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)